Sandbox:Usman Shah: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 21: Line 21:
== Classification ==
== Classification ==


* COVID-19-related ARDS was divided into three categories based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O: mild (200 mmHg ≤ PaO2/FiO2 < 300 mmHg), mild-moderate (150 mmHg ≤ PaO2/FiO2 < 200 mmHg), and moderate-severe (PaO2/FiO2 < 150 mmHg).<ref name="LiMa2020">{{cite journal|last1=Li|first1=Xu|last2=Ma|first2=Xiaochun|title=Acute respiratory failure in COVID-19: is it “typical” ARDS?|journal=Critical Care|volume=24|issue=1|year=2020|issn=1364-8535|doi=10.1186/s13054-020-02911-9}}</ref>
 
Authors in a case report highlighted the nonuniformity of patients with [[COVID-19]]-associated ARDS and proposed the existence of two primary [[phenotypes]]:
 
* Type L (low values of [[elastance]], pulmonary [[Ventilation/perfusion ratio|ventilation/ perfusion ratio]], lung weight, and recruitability).
* Type H (high values of [[elastance]], right-to-left shunt, lung weight, and recruitability), more consistent with typical severe [[Acute respiratory distress syndrome|ARDS]].<ref name="FanBeitler2020">{{cite journal|last1=Fan|first1=Eddy|last2=Beitler|first2=Jeremy R|last3=Brochard|first3=Laurent|last4=Calfee|first4=Carolyn S|last5=Ferguson|first5=Niall D|last6=Slutsky|first6=Arthur S|last7=Brodie|first7=Daniel|title=COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?|journal=The Lancet Respiratory Medicine|year=2020|issn=22132600|doi=10.1016/S2213-2600(20)30304-0}}</ref>
 
 
ARDS is divided into three categories based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O:  
 
* mild (200 mmHg ≤ PaO2/FiO2 < 300 mmHg),  
* mild-moderate (100 mmHg ≤ PaO2/FiO2 < 200 mmHg), and  
* moderate-severe (PaO2/FiO2 < 100 mmHg).<ref name="LiMa2020">{{cite journal|last1=Li|first1=Xu|last2=Ma|first2=Xiaochun|title=Acute respiratory failure in COVID-19: is it “typical” ARDS?|journal=Critical Care|volume=24|issue=1|year=2020|issn=1364-8535|doi=10.1186/s13054-020-02911-9}}</ref>
 
<br />
 
== Pathophysiology ==
 
*
*



Revision as of 13:45, 20 July 2020

Covid-19 Associated ARDS

Overview


Historical Perspective

  • On 31 December 2019, the World Health Organization (WHO) was formally notified about a cluster of cases of pneumonia in Wuhan City.[1]
  • Ten days later, WHO was aware of 282 confirmed cases, of which four were in Japan, South Korea and Thailand
  • The virus responsible was isolated on 7 January and its genome shared on 12 January.The cause of the severe acute respiratory syndrome that became known as COVID‐19 was a novel coronavirus, SARS‐CoV‐2
  • ARDS is one of the most important causes of hospital and ICU admission due to COVID.
  • Many autopsies studies reported ARDS to be the cause of death in patients dying due to respiratory complications of COVID.
  • As of July 19 2020 the number of total cases worldwide are 14,043,176 including 597,583 deaths, reported to WHO.


Classification

Authors in a case report highlighted the nonuniformity of patients with COVID-19-associated ARDS and proposed the existence of two primary phenotypes:


ARDS is divided into three categories based on oxygenation index (PaO2/FiO2) on PEEP ≥ 5 cmH2O:

  • mild (200 mmHg ≤ PaO2/FiO2 < 300 mmHg),
  • mild-moderate (100 mmHg ≤ PaO2/FiO2 < 200 mmHg), and
  • moderate-severe (PaO2/FiO2 < 100 mmHg).[3]


Pathophysiology

Covid19 healthcare worker. [1]


Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -

[4] [1]


Infra-Hisian Block Microchapters

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Treatment

Prevention

Differentiating Infra-Hisian Block from other Diseases




References

  1. 1.0 1.1 Chaplin, Steve (2020). "COVID ‐19: a brief history and treatments in development". Prescriber. 31 (5): 23–28. doi:10.1002/psb.1843. ISSN 0959-6682. line feed character in |title= at position 6 (help)
  2. Fan, Eddy; Beitler, Jeremy R; Brochard, Laurent; Calfee, Carolyn S; Ferguson, Niall D; Slutsky, Arthur S; Brodie, Daniel (2020). "COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?". The Lancet Respiratory Medicine. doi:10.1016/S2213-2600(20)30304-0. ISSN 2213-2600.
  3. Li, Xu; Ma, Xiaochun (2020). "Acute respiratory failure in COVID-19: is it "typical" ARDS?". Critical Care. 24 (1). doi:10.1186/s13054-020-02911-9. ISSN 1364-8535.
  4. Kiran U, Aggarwal S, Choudhary A, Uma B, Kapoor PM (2017). "The blalock and taussig shunt revisited". Ann Card Anaesth. 20 (3): 323–330. doi:10.4103/aca.ACA_80_17. PMC 5535574. PMID 28701598.